In recent years, under the environment of continuous deepening of medical reform and various medical reform policies, the reshuffle of the pharmaceutical market has intensified
.
It is reported that since 2022, while the concentration of the pharmaceutical market has increased, a large number of pharmaceutical companies have stopped production, cancelled their certificates and no longer operate
.
Industry analysts believe that in the context of intensified changes in the pharmaceutical market, there are three major challenges that will continue to affect the development of pharmaceutical companies
.
The reform of the pharmaceutical market has intensified, and pharmaceutical companies are facing three major challenges! (Image source: Pharmaceutical Network)
Centralized impact
Centralized impact
Up to now, the National Medical Insurance Administration has carried out 7 batches of centralized procurement of state-organized drugs
.
For the winning bidders, centralized procurement is bringing a lot of volume to the follow-up market of a large number of pharmaceutical companies through the principle of exchanging price for volume
.
However, it should be noted that, at the same time, with the expansion of market share after entering the centralized procurement, the supply volume has increased sharply, and the infrastructure construction capabilities of the winning bidders are also facing huge tests
.
In addition, for companies that did not win the bid, they are also facing crises such as product price cuts
.
In addition to pharmaceutical companies, pharmaceutical representatives are also a group greatly affected by centralized procurement
.
With the normalization of centralized procurement forcing the price of medicines to decrease, the winning bidders are constantly disbanding their sales teams in exchange for price, and the life of medical representatives has become more and more difficult
.
Some people in the industry pointed out that due to the impact of centralized procurement, the positions of medical representatives have decreased by at least about 15%-20% compared with three years ago, and most of the reduced positions are in centralized procurement products, especially products in the field of cardiovascular endocrinology
.
The industry expects that due to the normalization of centralized procurement, the pharmaceutical market environment will become more volatile in the future.
How should pharmaceutical companies respond? The industry believes that one of the purposes of centralized procurement is to squeeze out inflated drug prices, forcing pharmaceutical companies to innovate and transform
.
Therefore, for pharmaceutical companies, they should focus on the research and development of innovative drugs and first generic drugs, and constantly improve their product pipelines and reserve advantageous products to continuously improve their competitiveness and market position
.
For medical practitioners, continuous improvement of their professional capabilities may make them more competitive in the market
.
Senior executives leave frequently
Senior executives leave frequently
In recent years, executives in the pharmaceutical industry have changed frequently.
Since 2022, more than 150 executives of pharmaceutical companies have left, involving multinational pharmaceutical companies, local Biotech, traditional pharmaceutical companies, and Internet medical companies
.
In fact, the frequent changes of executives in the pharmaceutical industry are closely related to the development of the industry
.
In recent years, under the continuous promotion of the medical reform policy, the domestic pharmaceutical industry is undergoing earth-shaking changes.
For example, with the continuous deepening of centralized procurement and the continuous expansion of varieties, the profit of the generic drug business has shrunk, which is forcing pharmaceutical companies to accelerate their transformation.
.
.
In In this context, it has become the norm for companies to adjust their development strategies and make active personnel adjustments
.
Industry insiders believe that with the deepening of domestic pharmaceutical reforms, the changes in executives of domestic pharmaceutical companies will continue
.
In this context, the future requirements for talents in the pharmaceutical industry are expected to have three main characteristics: first, the threshold for professional quality is relatively high; second, practitioners are required to have strong compliance capabilities
.
The third is to be able to adapt to changes in the market
.
Competition in the innovation market continues to intensify
Competition in the innovation market continues to intensify
In recent years, round after round of centralized drug procurement has been accelerating the reform of the domestic pharmaceutical industry
.
While continuously promoting the domestic substitution of original research drugs, it has also begun to continuously promote many pharmaceutical companies to increase their research and development to seek transformation
.
It is understood that in recent years, the innovation and R&D investment of local pharmaceutical companies has continued to rise
.
Among them, the R&D investment of large-scale enterprises has an average annual growth rate of about 8%, and the R&D expenses of listed companies will account for more than 6% of sales revenue in 2020
.
In addition to increasing investment in research and development, many pharmaceutical companies have also made it clear that innovative drugs are the main direction of their own development.
On the whole, it is obvious that innovation has become the general trend of the development of domestic pharmaceutical companies, and in this context, the number of innovative drugs in China is also growing exponentially
.
However, it should be noted that the threshold for research and development of innovative drugs is high.
At present, the innovation capability of domestic pharmaceutical companies is weak, and most pharmaceutical companies are still in the stage of Me-too new drug research and development
.
In addition, some innovative hot tracks such as ADC drugs and PD-1 products are becoming more and more "involutionary", and the amount of fundraising and financing is also getting higher and higher, and the competition has become quite fierce
.
According to statistics, 85 Chinese companies have developed or cooperated to develop PD-1 products in China, and it is expected that 15 PD-1 mAbs will be launched in the next 2-3 years
.
Therefore, the industry believes that pharmaceutical companies should try their best to realize the clinical value of product differentiation while increasing investment in research and development, strive to realize the value of innovative drugs in the international market, improve enterprise management capabilities, and formulate scientific sales model selection and commercialization.
Only by promoting strategies can we find new ways for the development of more innovative drugs
.
